Effect of St John's wort (Hypericum perforatum) on cytochrome P-450 activity in perfused rat liver

被引:46
作者
Dostalek, M
Pistovcakova, J
Jurica, J
Tomandl, J
Linhart, I
Sulcová, A
Hadasova, E
机构
[1] Masaryk Univ, Fac Med, Dept Pharmacol, Brno 60200, Czech Republic
[2] Masaryk Univ, Fac Med, Dept Biochem, Brno 66243, Czech Republic
[3] Inst Chem Technol, Dept Organ Chem, CR-16628 Prague, Czech Republic
关键词
St. John's wort; cytochrome P-450; drug interactions;
D O I
10.1016/j.lfs.2005.04.055
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 [基础医学];
摘要
St. John's wort (Hypericum perforatum) is a popular over-the-counter dietary supplement and a herbal antidepressant that has been implicated in drug interactions with substrates of several cytochrome P-450 (CYP) isozymes. The effects of the St. John's wort extract (100 mg/kg, i.p., once daily for 10 days) on metabolic activity of CYP450 were assessed in the system of isolated perfused rat liver. The substrates used in this study were tolbutamide (CYP2C6), dextromethorphan (CYP2D2) and midazolam (CYP3A2). Validated HPLC method was used to quantify all compounds of interest. St. John's wort administration affected CYP activity, causing a significant decline in AUC of dextromethorphan [F(4,3 1)= 1511, p < 0.001; PLSD, p < 0.001] and AUC of midazolam [ F(3,25)=221, p < 0.001; PLSD, p =0.035] and a significant increase in AUC of tolbutamide [F(3,26)=200,p < 0.001; PLSD,p < 0.001]. St. John's wort administration resulted in a significant induction of CYP2D2 and CYP3A2, and in a significant inhibition of CYP2C6 metabolic activities. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:239 / 244
页数:6
相关论文
共 40 条
[1]
Drug interaction between St. John's wort and cyclosporine [J].
Barone, GW ;
Gurley, BJ ;
Ketel, BL ;
Lightfoot, ML ;
Abul-Ezz, SR .
ANNALS OF PHARMACOTHERAPY, 2000, 34 (09) :1013-1016
[2]
Differential effects of Saint John's Wort (hypericum perforatum) on the urinary excretion of D-glucaric acid and 6β-hydroxycortisol in healthy volunteers [J].
Bauer, S ;
Störmer, E ;
Kerb, R ;
Johne, A ;
Brockmöller, J ;
Roots, I .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (09) :581-585
[3]
BILIA AR, 2002, LIFE SCI, V70, P1
[4]
Drug interaction of St John's wort with ciclosporin [J].
Breidenbach, T ;
Hoffmann, MW ;
Becker, T ;
Schlitt, H ;
Kiempnauer, J .
LANCET, 2000, 355 (9218) :1912-1912
[5]
Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: A double-blind, randomized pilot study [J].
Brenner, R ;
Azbel, V ;
Madhusoodanan, S ;
Pawlowska, M .
CLINICAL THERAPEUTICS, 2000, 22 (04) :411-419
[6]
Hyperforin as a possible antidepressant component of hypericum extracts [J].
Chatterjee, SS ;
Bhattacharya, SK ;
Wonnemann, M ;
Singer, A ;
Müller, WE .
LIFE SCIENCES, 1998, 63 (06) :499-510
[7]
Methodologies to study the induction of rat hepatic and intestinal cytochrome P450 3A at the mRNA, protein, and catalytic activity level [J].
Cotreau, MM ;
von Moltke, LL ;
Beinfeld, MC ;
Greenblatt, DJ .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2000, 43 (01) :41-54
[8]
Drug interaction between St John's wort and nevirapine [J].
de Maat, MMR ;
Hoetelmans, RMW ;
Mathôt, RAA ;
van Gorp, ECM ;
Meenhorst, PL ;
Mulder, JW ;
Beijnen, JH .
AIDS, 2001, 15 (03) :420-421
[9]
Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.) [J].
Ernst, E ;
Rand, JI ;
Barnes, J ;
Stevinson, C .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (08) :589-594
[10]
Ghosal A, 1996, DRUG METAB DISPOS, V24, P940